Robert J. Oldham

This study shows that Fc receptor engagement is necessary for the efficacy of SARS-CoV-2 therapeutics, including mAbs and BiKEs, and demonstrates the effectiveness of ACE2 decoy Fc-fusions and BiKEs against multiple variants.

This paper introduces LAffAb, a method to co-optimize antibody affinity and stability through combinatorial mutation design, achieving significant affinity gains while maintaining developability.

This study shows that FcγRIIb promotes α-syn propagation and neurotoxicity in vivo, suggesting it as a therapeutic target for synucleinopathies.